Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> V600–Mutant Adult Glial and Glioneuronal TumorsGiulia Berzero, Anna Luisa Di Stefano, Antonio Silvani et al.|Neurology|2021Cited by 30
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancersCapucine Baldini, Aurélien Marabelle|Journal of Experimental & Clinical Cancer Research|2022Cited by 28
Abstract 4608: Evaluation of the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitorsKimberly J. Briggs, Adam Crystal, Andre Mignault et al.|Cancer Research|2025Cited by 0